LASSBio-1828(LASSBio-1828) - 药物靶点：p38 MAPK_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点

p38 MAPK

作用方式

抑制剂

作用机制

p38 MAPK抑制剂(P38丝裂原活化蛋白激酶抑制剂)

治疗领域

其他疾病

在研适应症-

非在研适应症

炎症

原研机构

Federal University of Rio de Janeiro

在研机构-

非在研机构

Federal University of Rio de Janeiro

权益机构-

最高研发阶段无进展临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 LASSBio-1828 相关的临床结果

登录后查看更多信息

100 项与 LASSBio-1828 相关的转化医学

登录后查看更多信息

100 项与 LASSBio-1828 相关的专利（医药）

登录后查看更多信息

1

项与 LASSBio-1828 相关的文献（医药）

2020-03-01·Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2区 · 医学

New 2-amino-pyridinyl-N-acylhydrazones: Synthesis and identification of their mechanism of anti-inflammatory action

2区 · 医学

Article

作者: Fernandes, Patricia Dias ; Cordeiro, Natalia de Morais ; Freitas, Rosana H C N ; Fraga, Carlos Alberto Manssour

AIMS:

The main aim of this paper was the synthesis and the evaluation of the anti-inflammatory activity of LASSBio-1828 (an amino-pyridinyl-N-acylhydrazone) and its respective hydrochloride, based on a p38α MAPK inhibitor (LASSBio-1824) previously synthesized by our group.

MAIN METHODS:

The compounds were tested regarding their cell viability effect and on acute models of inflammation such as formalin-induced licking test, cell migration and inflammatory mediators quantification.

KEY FINDINGS:

Treatment with the compounds inhibited p38α, reduced inflammatory pain, cell migration and inflammatory mediators that participate on the MAPK pathway such as TNF-α and IL-1β.

SIGNIFICANCE:

Taken together, these results suggest that the synthesis of the corresponding hydrochloride of LASSBio-1828 enhanced its potency as a p38 inhibitor, and also that this compound could be considered a good anti-inflammatory drug candidate after further studies.

100 项与 LASSBio-1828 相关的药物交易

登录后查看更多信息